Proactive Investors - Run By Investors For Investors

Scancell says it is working closely with US regulators ahead of phase II study of cancer immunotherapy

The UK group is planning to use its SCIB1 in harness with Merck’s Keytruda to treat patients with advanced melanoma
woman researcher working in lab
The company hopes the study will get underway in the first half of next year

Scancell Holdings Plc (LON:SCLP) said it is working closely with the US drugs regulator to address questions raised ahead of the launch of a phase II clinical study of its cancer immunotherapy.a

The UK group is planning to use its SCIB1 in harness with Merck’s Keytruda to treat patients with advanced melanoma.

Ahead of granting investigational new drug status, America’s Food & Drug Administration has requested some additional information.

Focus on TriGrid

The queries are focused on a technology called TriGrid, a delivery system developed by Ichor Medical Systems that is also part of the combination therapy.

Chief executive Cliff Holloway said: "We are working closely with Ichor and the FDA to address the questions they have raised and we are confident we can respond to these in a timely manner. 

“We continue to advance the operational processes and procedures to ensure a rapid start to the study once approval is obtained."

Subject to regulatory sign-off, Scancell expects patient enrolment to begin in the first half of next year.

View full SCLP profile View Profile

Scancell Holdings PLC Timeline

Related Articles

skin cream
October 25 2018
The cream is currently undergoing its first-in-human studies, with researchers assessing its skin irritancy, moisturisation potential and skin barrier function
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use